Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative disease

Abstract

Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.

1 . A method of inducing apoptosis in a cell in a mammal diagnosed as having a proliferative disease, said method comprising administering to said mammal a modified antisense oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense oligonucleotide is complementary to a portion of human IAP-1 (HIAP-1) (SEQ ID NO:5).  
     
     
         2 . A method of treating a patient diagnosed as having a proliferative disease, said method comprising administering to said patient a modified antisense oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense oligonucleotide is complementary to a portion of human IAP-1 (HIAP-1) (SEQ ID NO:5).  
     
     
         3 . The method of  claim 2 , wherein said mammal is a human.  
     
     
         4 . The method of  claim 2 , wherein said proliferative disease is cancer.  
     
     
         5 . The method of  claim 4 , wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.  
     
     
         6 . The method of  claim 1 , wherein said mammal is a human.  
     
     
         7 . The method of  claim 1 , wherein said proliferative disease is cancer.  
     
     
         8 . The method of  claim 7 , wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.